Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MLLT10 pseudogene 2 (MLLT10P2) is a genomic pseudogene, which means it is a non-functional copy derived from the MLLT10 gene[1]. Unlike MLLT10, which encodes a protein cofactor for DOT1L and plays roles in transcriptional regulation and chromatin modification associated with leukemias[3][5][9], MLLT10P2 does not produce a protein or perform biological functions. Pseudogenes are widely distributed in the genome and generally do not serve as direct drug targets or receptors. The biological and therapeutic relevance of MLLT10P2 is minimal; it is primarily of interest for genomic annotation rather than medicinal or pharmacological purposes[1]. For genuine therapeutic targets related to this family, refer to the functional MLLT10 gene and protein, sometimes called AF10, which participates in transcriptional and chromatin-remodeling complexes with roles in acute myeloid leukemia and other cancers[3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MLLT10 pseudogene 2 (MLLT10P2).